| P50 | author | Don J. Diamond | Q37374385 |
| | David I Quinn | Q38327794 |
| | Simon F Lacey | Q56978267 |
| | Timothy Synold | Q78536675 |
| | Janice P Dutcher | Q90323603 |
| P2093 | author name string | Paul Frankel | |
| | David R Gandara | |
| | Kim Margolin | |
| | Bixin Xi | |
| | Primo Lara | |
| | Tracey Baratta | |
| P2860 | cites work | New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 |
| | The Bcl-2 protein family: arbiters of cell survival | Q29618158 |
| | Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma | Q33332247 |
| | Interferon in metastatic renal cell carcinoma. | Q33893635 |
| | Interleukin-2 in the treatment of renal cancer | Q33893642 |
| | Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. | Q35833088 |
| | Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. | Q35839316 |
| | bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer | Q35977975 |
| | Antisense strategies for oncogene inactivation | Q36336373 |
| | A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer | Q40492457 |
| | Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. | Q40497868 |
| | Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase. | Q40503953 |
| | A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer | Q40528459 |
| | Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia | Q40572385 |
| | Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides | Q41543910 |
| | Expression of the bcl-2 gene product in follicular lymphoma | Q41823145 |
| | Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer | Q42457244 |
| | bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis | Q42487605 |
| | Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma | Q42507253 |
| | Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer | Q44799726 |
| | A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer | Q46493707 |
| | Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry | Q46660133 |
| | Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. | Q50771779 |
| | The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. | Q52378630 |
| | Expression of bcl-2 in small cell lung carcinoma cells. | Q54218040 |
| | Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) | Q59085244 |
| | Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells | Q68101483 |
| | Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas | Q71566389 |
| | Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: evidence for the contribution of bcl-2 expression to renal carcinogenesis | Q71639948 |
| | Immunomodulating therapy with rIL-2 and interferon alpha-induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study) | Q73341871 |
| | Renal lesions in von Hippel-Lindau disease: immunohistochemical expression of nephron differentiation molecules, adhesion molecules and apoptosis proteins | Q73738803 |
| | Bcl-2 modulates Fas-mediated apoptosis in human renal cell carcinoma cell lines | Q73878319 |
| | The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways | Q74404388 |
| P433 | issue | 10 | |
| P921 | main subject | California | Q99 |
| P304 | page(s) | 705-711 | |
| P577 | publication date | 2007-05-17 | |
| P1433 | published in | Journal of Cancer Research and Clinical Oncology | Q2081599 |
| P1476 | title | Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium | |
| P478 | volume | 133 | |